Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.
about
Glia and alpha-synuclein in neurodegeneration: A complex interactionNeuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunitySeeking a mechanism for the toxicity of oligomeric α-synucleinAssessment of α-synuclein secretion in mouse and human brain parenchymaClinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.The role of Galectin-3 in α-synuclein-induced microglial activation.Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation.Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotypeDopaminergic Toxin 1-Methyl-4-Phenylpyridinium, Proteins α-Synuclein and Glia Maturation Factor Activate Mast Cells and Release Inflammatory Mediators.Eicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor.Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T MutantEpigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.Alpha-synuclein: from secretion to dysfunction and death.Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?The role of glia in α-synucleinopathies.Dysfunction of two lysosome degradation pathways of α-synuclein in Parkinson's disease: potential therapeutic targets?The role of inflammation in sporadic and familial Parkinson's disease.Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like PropagationCompromised MAPK signaling in human diseases: an update.New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation.Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy.Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegenerationThe gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia.Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia.Screening of Toll-like receptors expression in multiple system atrophy brains.Microglial Phagocytosis and Its Regulation: A Therapeutic Target in Parkinson's Disease?Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment.Microglia Response During Parkinson's Disease: Alpha-Synuclein InterventionAn Overview of Methods to Study MicrogliaOutside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
P2860
Q26851153-711566C9-A9F4-492B-ABE4-D540589D2639Q27027973-427B318D-A637-4FB7-972C-47A4CD704B9AQ28080551-FE507932-94EF-41B0-AD01-0C529F25CBEBQ28479033-577DEE37-304B-401D-8B52-764B3B4ABB77Q30544056-D9B8648B-D9FF-45ED-9E4A-6333C6D01B7BQ34537231-DD01931F-FB23-4935-A093-86D11169A1A6Q34994184-F3AE6179-220E-44C5-8D97-1F87B5B40EDFQ35043731-166F67C3-5277-4DDC-85E8-785B83D0D3BAQ35285839-FC7F415D-A735-4E08-9685-5FE0A5167313Q35746518-7D025C34-B2BA-4AA7-9B24-CB87C610BBF2Q36055556-F9F90B19-E23D-45C8-9C35-7035FD79FBD1Q36131340-51AB6A16-9569-4FFF-86F9-F11F6F74E406Q36648907-F4ABA851-DDF5-4039-8C01-14BAD2BDBA76Q37874476-34DBA56F-F345-4861-8BF4-5841FF5B69E5Q38028819-8AD6E6A7-3ED1-4BE5-AAAE-ADB3F56A8B2BQ38032481-FE72C086-4BB5-45C0-A391-5BB48BD09C01Q38039880-31A98001-FDB1-4F85-B77D-182FF89E8EC8Q38041991-606578E4-49D9-4A2F-AB51-44EE9B9F1ABAQ38105903-560BED34-7149-486D-9F01-AE17EA5E21BEQ38303579-1DF6C11A-4F95-4588-AE14-C366AA4548CBQ38359194-88B7D6DE-3407-4208-A6E0-6A8350C2397EQ38430373-F365E373-5657-447A-A109-699D0AFB2BD9Q39209459-9A8A7B5B-B1BB-4484-86D2-9A7E9D48D074Q39327711-4D1C301A-2005-43E2-9580-25609456922FQ41761790-25F00645-D6FD-416C-A75D-24B145AAF2A0Q41997706-AA72FB84-94AE-4040-B933-53274220E2F6Q44294417-2A948D4E-B681-42DA-9515-F909E27AC7E5Q54942358-B398B074-AE54-4183-8428-A428F5FF763EQ54958949-B3640BA8-2F75-40A3-8637-CF8C02FAED7EQ58799080-7A17C6DD-7026-4B9C-B6B5-B34EF328197BQ58799132-A497A724-4EA7-42D6-969C-5BE99DC08FBCQ59136331-44A2B7F9-58F5-48E6-BB71-DFA181368A15
P2860
Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Glial innate immunity generate ...... nson's disease-linked mutants.
@ast
Glial innate immunity generate ...... nson's disease-linked mutants.
@en
type
label
Glial innate immunity generate ...... nson's disease-linked mutants.
@ast
Glial innate immunity generate ...... nson's disease-linked mutants.
@en
prefLabel
Glial innate immunity generate ...... nson's disease-linked mutants.
@ast
Glial innate immunity generate ...... nson's disease-linked mutants.
@en
P2093
P2860
P50
P1433
P1476
Glial innate immunity generate ...... nson's disease-linked mutants.
@en
P2093
Adahir Labrador-Garrido
Marta Caro
Rafael Fernandez-Montesinos
P2860
P304
P356
10.1371/JOURNAL.PONE.0013481
P407
P50
P577
2010-10-26T00:00:00Z